Salmedix was a start-up biotechnology firm focused on discovering and developing minimally-toxic therapies to treat cancers, particularly those that affect the growing global geriatric population. The company was acquired by Cephalon in May 2005.
Investors 3
Mentions in press and media 3
| Date | Title | Description | Source |
| 08.03.2024 | Epilepsy Surgery Market Worth $1483.5 Mn by 2030 Driven by I... | Epilepsy Surgery Market Epilepsy Surgery Market Analysis, Trends, Industry Overview, and Growth Outl... | einpresswi... |
| 08.06.2011 | FDA’s REMS program puts BDSI at a disadvantage in cancer dru... | BDSI has been working with the FDA on changes to get its lead product on the same footing as its com... | medcitynew... |
| - | FDA’s REMS program puts BDSI at a disadvantage in cancer dru... | Commercializing a new drug in the face of strict U.S. Food and Drug Administration guidelines is tou... | medcitynew... |